Favipiravir (T-705)

製品コードS7975 バッチS797505

化学情報

	Synonyms	N/A	Storage (From the date of receipt)	3 years -20°C powder 1 years -80°C in solvent
	化学式	C₅H₄FN₃O₂
	分子量	157.1	CAS No.	259793-96-9
Solubility (25°C)*	体外	DMSO	31 mg/mL (197.32 mM)
		Water	2 mg/mL warmed with 50ºC water bath (12.73 mM)
		Ethanol	2 mg/mL warmed with 50ºC water bath (12.73 mM)
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.
in vitro	Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 μg/ml. ^[1] In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis. ^[2]
in vivo	In influenza virus-infected mice, Favipiravir (200 mg/kg/day, p.o.) protects the mice from death from influenza virus infection. ^[1] In mice experimentally infected with Ebola virus, Favipiravir efficiently blocks viral production, reaching an antiviral effectiveness of 95% and 99.6% at 2 and 6days after initiation of treatment, respectively. ^[3]

プロトコル(参考用のみ)

細胞アッセイ	細胞株	MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells
	濃度	1000 μg/mL
	反応時間	3 days
	実験の流れ	The cytotoxicity of T-705 is evaluated by an assay with XTT. XTT is converted to aqueous formazan by an enzyme in MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells. The compounds are diluted to the appropriate concentrations (volume, 100 μl) with test medium (EMEM containing 10% FCS) in 96-well culture plates in which each well contains a concentration of 2 × 10³ cells/100 μL. The test plates are incubated for 3 days at 37°C in 100% humidity and 5% CO₂. After 3 days, 50 μl of the XTT reagent (1 mg/ml in FCS-free EMEM containing 5 mM phenazine methosulfate) is added, and the reaction product is assayed by measurement of the absorbance at 450 nm with a microplate reader. Cytotoxicity is expressed as the 50% cell-inhibitory concentration (CC50).
動物実験	動物モデル	Mice infected with influenza virus A/PR/8/34
	投薬量	200 mg/kg/day
	投与方法	p.o.

参考

カスタマーフィードバック

: Data from [Data independently produced by , , Cell Physiol Biochem, 2018, 49(1):381-394]

: Data from [Data independently produced by , , Antiviral Res, 2017, 143:237-245]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus [ J Med Virol, 2024, 96(1):e29372]	PubMed: 38235544
Ebola virus VP35 hijacks the PKA-CREB1 pathway for replication and pathogenesis by AKIP1 association [ Nat Commun, 2022, 13(1):2256]	PubMed: 35474062
TRIM25 inhibits influenza A virus infection, destabilizes viral mRNA, but is redundant for activating the RIG-I pathway [ Nucleic Acids Res, 2022, gkac512]	PubMed: 35736141
In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimean-Congo hemorrhagic fever virus [ Antiviral Res, 2022, 199:105273]	PubMed: 35257725
Novel Antiviral Activity of Ethyl 3-Hydroxyhexanoate Against Coxsackievirus B Infection [ Front Microbiol, 2022, 13:875485]	PubMed: 35495645
Favipiravir induces oxidative stress and genotoxicity in cardiac and skin cells [ Toxicol Lett, 2022, 371:9-16]	PubMed: 36152797
Use of liquid chromatography-tandem mass spectrometry for foscarnet quantification in human serum and cerebrospinal fluid [ Rapid Commun Mass Spectrom, 2022, e9255]	PubMed: 35001441
A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase [ Antiviral Res, 2021, S0166-3542(21)00068-1]	PubMed: 33894278
Engineering a Reliable and Convenient SARS-CoV-2 Replicon System for Analysis of Viral RNA Synthesis and Screening of Antiviral Inhibitors [ mBio, 2021, 12(1)e02754-20]	PubMed: 33468688
Comprehensive Cardiotoxicity Assessment of COVID-19 Treatments Using Human Induced Pluripotent Stem Cell-derived Cardiomyocytes [ Toxicol Sci, 2021, kfab079]	PubMed: 34142159

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。